cellNUA Announces Breakthrough Immunotherapeutic Platform to Combat Global Pathogenic Diseases
Galway, Ireland – cellNUA Teoranta, an innovative Irish biotech company – announces BEEMAR™, the world’s first versatile, natural and scalable platform to protect against multiple pathogenic threats: viruses, bacteria and parasites. What does BEEMAR™ draw on? The immune system of the honeybee.
“The honeybee shares more similarities with humans than with other insects, with ancient genes that were lost in the line of evolution. Lucky us”, says cellNUA’s head of science Dr Rania el Helou. “Long before written language was invented, long before man discovered fire and centuries before the first villages were built; the inherent bee survived many apocalyptic pathogens. Bees possess ‘Knockdowns mechanisms’ capable of fighting pathogens that afflict humans and mammals, both for their own evolution and probably altruistically.”
High potential medicine grounded in science and ethics is what is at the heart of cellNUA. As the World Health Organisation rallies for advancements and safety in immune therapies, we act on that. With pioneering research, the bee hive becomes our bioreactor, for natural new immune therapies. This is life-changing.
Uncovered shared immunological pathways between honeybee and human, working through comparative genomics, enable cellNUA to reproduce the inoculations bee hives create against pathogens. With our innovative patented technique, we can then present a safe form of a huge variety of specific and new pathogens, and the bioreactor then gets to work.
The beehive’s rapid and targeted immune response produces therapeutic factors that can be extracted, and formulated, into medicines for human use. This is BEEMAR™.
“We believe BEEMAR™ will be the world’s first natural, synthetic-free immunotherapeutic platform to partner with the body’s cells to produce critical reinforcement against pathogenic threats,” says John Kelleher, Executive Chairman of cellNUA.
The BEEMAR™ platform has already demonstrated 99.99% efficacy against diverse virus families in laboratory trials, including influenza, polio, herpes, and the common cold; and in preclinical trials against COVID-19. Upcoming human trials will further validate the platform’s potential to combat major global diseases like malaria, Dengue Fever virus, MERS and SARS.
cellNUA have also demonstrated the potential of the BEEMAR™ Platform against parasites such as Malaria. Working with the Noguchi Memorial Institute for Medical Research in Ghana pre-clinical trials demonstrate the effectiveness of the therapy against the parasite that causes Malaria. Clinical trials are now scheduled for Q1 2025. Initial cell-based assays validated the enhanced efficacy of BEEMARTM, against leading pharmaceutical drugs, and without the normally associated side effects, or cytotoxicity. Pre-clinical trials further validated the capacity of the platform technology in treating the parasite that causes malaria, Plasmodium – and, as a result, preparations are in hand to run clinical trials in Ghana in 2025
Through strategic partnerships, cellNUA is establishing regional “BioCities” worldwide, enabling local, sustainable production of critical therapies and vaccines. This transformative model empowers governments to protect citizens from both known diseases and future pandemic threats.
The support of Údarás na Gaeltachta, the regional authority responsible for the economic, social and cultural development of the Gaeltacht, has been crucial to cellNUA’s success. Declan Clarke, CEO cellNUA Teoranta, recognizes the importance of being in the Gaeltacht, an area where the Irish language is the primary language spoken, has a rich and creative talent pool and is committed to contributing to the region’s growth and prosperity.
Tomás Ó Síocháin, CEO of Údarás na Gaeltachta, emphasized the significance of cellNUA’s presence in the region: “cellNUA’s establishment in the Gaeltacht represents a major step forward for our community. By bringing cutting-edge industries to the area, we are providing Irish-speaking graduates with the opportunity to work in groundbreaking fields while maintaining their connection to the language and culture. This is a prime example of how we can foster innovation and economic growth in the Gaeltacht.”
“Our vision is to deliver scientifically advanced, naturally inspired interventions to treat the most challenging diseases known to mankind,” says Kelleher. “BEEMAR™ has the potential to revolutionize healthcare on a global scale. We are proud to be based in the Gaeltacht and grateful for the unwavering support of Údarás na Gaeltachta in helping us achieve our goals.”
For more information, please visit www.cellnua.com.